Brisbane, Australia, 21st-22nd November 2020: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer has partnered with HealthCert, the leading professional education provider for skin cancer management and treatment. DermaSensor will show its breakthrough technology to attendees at the HealthCert event held at the Brisbane Convention and Exhibition Centre in November this year.
HealthCert International is a global organisation that delivers comprehensive GP education and universal access to diagnosis and treatment tools dedicated to achieve better patient outcomes. It provides medical and patient education, skin cancer centres where patients can access head-to-toe skin checks, lesion diagnosis and treatment, and TeleDermatology to enable quick diagnosis and treatment recommendations on skin cancer and general dermatology cases.
Kevin Scrimshaw, Commercial Director, ANZ and Martina Clark Territory Business Manager, VIC Australia from the DermaSensor team will demonstrate the DermaSensor device to the audience, and show how quick and easy it is to use. The handheld device brings Elastic Scattering Spectroscopy into a handheld device and uses world-first technology to augment the skills and experience clinicians use in decision making. It gives doctors an accurate differentiation between malignant and benign skin lesions in just a few seconds. A recent clinical study found that DermaSensor achieved a sensitivity of 100 percent for detecting melanoma and 94 percent for detecting nonmelanoma skin cancer.
“We are pleased to present a skin health assessment tool that’s efficient, accurate and affordable. DermaSenor uses objective spectroscopy and machine learning to assess a lesion and give a risk-based rating in under 30 seconds,” explains Kevin.
The technology was pioneered at Boston University and University College London. Elastic Scattering Spectroscopy is a non-invasive technique that uses light of varying wavelengths. A physician gently touches the non-invasive device tip to a selected mole or lesion and a spectral sensor records how dozens of wavelengths of light reflect off cells beneath the surface of the skin. A proprietary algorithm instantly analyses the reflected photons to give the physician a simple “Higher Risk” or “Lower Risk” rating to support their referral decision. It complements the physician’s skill and experience by using the power of machine learning to support clinical evaluation.
Over the last three years DermaSensor has miniaturised its spectroscopy technology into an easy-to-use handheld device. Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and it allows medical practitioners to spend less time on lengthy procedures.
The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. The DermaSensor device is low-cost and easy-to-use. It enables healthcare providers and patients to receive fast and accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.